Current Influenza Vaccine Strains
All 2024-2025 seasonal influenza vaccines in the United States are trivalent formulations containing three viral strains: one influenza A(H1N1), one influenza A(H3N2), and one influenza B/Victoria lineage virus. 1
2024-2025 Season Composition
The current influenza vaccines contain hemagglutinin derived from the following strains:
- Influenza A(H1N1) component: Unchanged from previous season 1
- Influenza A(H3N2) component: Different this season compared to last season 1
- Influenza B/Victoria lineage component: Unchanged from previous season 1
Important Change: Removal of B/Yamagata Lineage
Influenza B/Yamagata lineage virus has been removed from all seasonal influenza vaccines for 2024-2025. 1 This represents a shift from the quadrivalent vaccines used in recent years back to trivalent formulations, as B/Yamagata has not been detected globally since 2020. 1
Historical Context of Vaccine Formulations
Evolution from Trivalent to Quadrivalent
Prior to 2024-2025, quadrivalent vaccines were the standard and contained four strains:
- Two influenza A strains (H1N1 and H3N2) 1
- Two influenza B strains (one from Victoria lineage and one from Yamagata lineage) 1
The rationale for quadrivalent vaccines was that the two influenza B lineages (Victoria and Yamagata) are antigenically distinct, and immunization against one lineage provides only limited cross-protection against the other. 1 This created challenges in predicting which B lineage would predominate each season, leading to potential mismatches when trivalent vaccines contained only one B strain. 1
Specific Historical Examples
For the 2021-2022 season, quadrivalent vaccines contained:
- A/Victoria/2570/2019 (H1N1)pdm09-like virus (egg-based) or A/Wisconsin/588/2019 (H1N1)pdm09-like virus (cell/recombinant-based) 1
- A/Cambodia/e0826360/2020 (H3N2)-like virus 1
- B/Washington/02/2019-like virus (Victoria lineage) 1
- B/Phuket/3073/2013-like virus (Yamagata lineage) 1
For the 2017-2018 season, trivalent vaccines contained:
- A/Michigan/45/2015 (H1N1)pdm09-like virus 1
- A/Hong Kong/4801/2014 (H3N2)-like virus 1
- B/Brisbane/60/2008-like virus (Victoria lineage) 1
Platform-Specific Variations
Different but antigenically related influenza A strains may be included in egg-based versus cell-based or recombinant vaccines within the same season, though all are matched to expected circulating strains. 1 This occurs because optimal viral characteristics differ by manufacturing platform. 1
Clinical Implications
The shift back to trivalent formulations does not represent reduced protection, but rather reflects the global disappearance of the B/Yamagata lineage. 1 The Advisory Committee on Immunization Practices and American Academy of Pediatrics make no preferential recommendation for any specific vaccine product when multiple age-appropriate options are available. 1, 2
Vaccination should not be delayed to obtain a specific product or formulation—timely vaccination with any available age-appropriate vaccine is the priority. 1, 2